array:24 ["pii" => "S2253808915000932" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.002" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "695" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:398-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 42 "formatos" => array:2 [ "HTML" => 25 "PDF" => 17 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X15000530" "issn" => "2253654X" "doi" => "10.1016/j.remn.2015.04.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "695" "copyright" => "Elsevier España, S.L.U. y SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:398-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 636 "formatos" => array:3 [ "EPUB" => 13 "HTML" => 392 "PDF" => 231 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "Imágenes de interés" "titulo" => "Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con 11C-metionina" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "398" "paginaFinal" => "399" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2374 "Ancho" => 3250 "Tamanyo" => 548019 ] ] "descripcion" => array:1 [ "es" => "A: estudio tras tratamiento Stupp. Imagen RM secuencia T1. Imagen RM secuencia Flair, Imagen de fusión PET/RM por software (SPM8). Imagen PET con 11C-metionina. La RM pone de manifiesto una lesión redondeada en la rodilla del cuerpo calloso, de 22x18, con edema vasogénico frontal anterior contiguo bilateral, que sugiere recidiva local. El estudio PET con 11C-metionina muestra un comportamiento hipermetabólico de esta lesión (relación SUV lesión/fondo 5,6/1,6) que confirma la recidiva tumoral. La cuantificación se realiza mediante la relación entre el grado de captación de la lesión (SUV máximo) y el fondo de sustancia gris del lóbulo contralateral sano (SUV medio). Figura 1-B: estudio tras tratamiento con bevacizumab. Imagen RM secuencia T1. Imagen RM secuencia Flair, Imagen de fusión PET/RM por software (SPM8). Imagen PET con 11C-metionina. La RM pone de manifiesto un aumento del tamaño de la lesión localizada en la rodilla del cuerpo calloso (27x24) con similar extensión del edema perilesional. El estudio PET con 11C-metionina muestra la resolución de la actividad metabólica en la lesión, confirmando la respuesta al tratamiento antiangiogénico, por lo que se continúa la terapia, sin signos posteriores que sugieran recidiva." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. García, M. Baquero, P. Bassa, M. Soler, M. Moragas, E. Riera" "autores" => array:6 [ 0 => array:2 [ "nombre" => "J.R." "apellidos" => "García" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baquero" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Bassa" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Soler" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Moragas" ] 5 => array:2 [ "nombre" => "E." "apellidos" => "Riera" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808915000932" "doi" => "10.1016/j.remnie.2015.09.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000932?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X15000530?idApp=UINPBA00004N" "url" => "/2253654X/0000003400000006/v1_201510300043/S2253654X15000530/v1_201510300043/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808915000944" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.003" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "721" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:400-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 88 "formatos" => array:2 [ "HTML" => 60 "PDF" => 28 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Special collaboration" "titulo" => "XXXV SEMNIM Congress. Highlights" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "400" "paginaFinal" => "411" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "XXXV Congreso de la SEMNIM. Conferencia Resumen" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0035" "etiqueta" => "Fig. 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 2346 "Ancho" => 3252 "Tamanyo" => 620104 ] ] "descripcion" => array:1 [ "en" => "FDG-PET and amyloid (florbetapir) in progressive primary logopenic aphasia. The number of amyloid-positive cases was high, thereby confirming its relationship with Alzheimer disease. These amyloid-positive subjects present a temporoparietal metabolic phenotype (FDG). The amyloid-negative group showed more extensive hypometabolism extending to the anterior temporal and frontal basal region and may correspond to frontotemporal degeneration (by Cabrera et al.; H. Clínico San Carlos)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Serena Puig" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Serena Puig" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X1500092X" "doi" => "10.1016/j.remn.2015.07.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X1500092X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000944?idApp=UINPBA00004N" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000944/v1_201510310036/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2253808915000920" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "690" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:396-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 57 "formatos" => array:2 [ "HTML" => 34 "PDF" => 23 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Interesting images" "titulo" => "18F-FDG PET/CT in a bilateral lacrimal gland infiltration of mantle cell lymphoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "396" "paginaFinal" => "397" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "18F-FDG PET/TC en un caso de infiltración lacrimal bilateral por linfoma de células del manto" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1887 "Ancho" => 3000 "Tamanyo" => 639144 ] ] "descripcion" => array:1 [ "en" => "T1 Spin-Echo sequences with selective fat suppression (SPIR) in the MRI before gadolinium i.v. injection (A), 18F-FDG PET/CT images (B, C and D) and Hematoxylin–Eosin staining (E). Images showed bilateral intraorbital lesions (A) which evidenced bilateral increased uptake of 18F-FDG in lacrimal glands (B), as well as supradiaphragmatic FDG-avid adenopathies (C and D). These findings are consistent with malignancy. Hematoxylin–Eosin staining of lacrimal gland (E) showed diffuse lymphomatous infiltration." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Martínez-Esteve, F.J. García-Gómez, J.J. Borrero-Martin, E. Fajardo-Pico, I. Borrego-Dorado" "autores" => array:5 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Martínez-Esteve" ] 1 => array:2 [ "nombre" => "F.J." "apellidos" => "García-Gómez" ] 2 => array:2 [ "nombre" => "J.J." "apellidos" => "Borrero-Martin" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Fajardo-Pico" ] 4 => array:2 [ "nombre" => "I." "apellidos" => "Borrego-Dorado" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X15000335" "doi" => "10.1016/j.remn.2015.03.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X15000335?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000920?idApp=UINPBA00004N" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000920/v1_201510310036/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "Interesting image" "titulo" => "Diagnosis of recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "398" "paginaFinal" => "399" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J.R. García, M. Baquero, P. Bassa, M. Soler, M. Moragas, E. Riera" "autores" => array:6 [ 0 => array:4 [ "nombre" => "J.R." "apellidos" => "García" "email" => array:1 [ 0 => "jrgarcia@cetir.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baquero" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Bassa" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Soler" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Moragas" ] 5 => array:2 [ "nombre" => "E." "apellidos" => "Riera" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad PET, CETIR-ERESA, Esplugues, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con 11C-metionina" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 3250 "Tamanyo" => 518779 ] ] "descripcion" => array:1 [ "en" => "(A) Imaging study after Stupp treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with 11C-Methionine. MR shows a rounded lesion located at the genu of corpus callosum measuring 22×18, with adjacent bilateral frontal angiogenic edema, consistent with local recurrence. PET with 11C-Methionine shows hypermetabolic lesion (SUV target/background ratio is 5.6/1.6), thus confirming tumor recurrence. Quantification was achieved through relationship between uptake avidity of the lesion (SUV maximum) and background of gray substance of the healthy contralateral lobe (SUV mean). (B) Imaging study after Bevacizumab treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with 11C-Methionine. MR shows an increase of size at the lesion located at the genu of corpus callosum (27×24), with similar perilesional edema spread. The PET study with 11C-Methionine shows normalization of previous metabolic activity in lesion, thus confirming response to antiangiogenic treatment, and therapy was carried on with no further suspicious signs of recurrence in our patient." ] ] ] "textoCompleto" => "A 60-year-old woman with history of multifocal glioblastoma surgically resected and treated with chemotherapy and radiotherapy, presented MR findings suspected of tumor recurrence. A PET with 11C-Methionine was performed, which showed high metabolic activity within the MR lesion, thus confirming a tumor recurrence (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Nowadays, it is widely accepted that the first therapeutic modality of glioma requires tumor resection as extensive as possible, followed by radiotherapy with neo-adjuvant, concomitant and adjuvant chemotherapy (Temozolomide-Temodal; Stupp protocol), with survival rates ranging from 10% to 40% by 2 years.<a class="elsevierStyleCrossRef" href="#bib0020">1</a>At present, there are also second-line treatments available for recurrent gliomas, including antiangiogenic therapies and targeted therapy based on genomic differentiation (methylated O-6-methylguanine-DNA methyltransferase gene promoter MGMT, epidermal growth factor receptor EGFR, IDH1 gene, 1p/19q deletion).A high amount of vascular epithelial growth factor-A (VEGF-A) is found in gliomas, due to their high proliferation rate. In 2009, the Food and Drug Administration approved the use of Bevacizumab (Avastin), a monoclonal antibody against the vascular endothelial growth factor, for the treatment of recurrent glioblastoma.<a class="elsevierStyleCrossRef" href="#bib0025">2</a>In our case, the MR study performed for monitoring of Bevacizumab therapy showed persistence of lesion, and even increasing size. Since tumor progression was suspected, a subsequent PET study with 11C-Methionine was repeated, which showed normalization of previous metabolic activity seen in lesion, thus confirming good response to antiangiogenic therapy (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B).Multiparametric MR is the first-line technique for the diagnosis of gliomas, as well as for post-treatment evaluation: early study after surgery and sequentially after chemo/radiotherapy. However, MR changes do not allow differentiating between radionecrosis and tumor recurrence in many cases. Changes in brain–blood barrier status secondary to antiangiogenic therapy may result in false-progression MR images (pseudo-progression).<a class="elsevierStyleCrossRef" href="#bib0030">3</a>PET with 11C-Methionine is indicated to differentiate between tumor recurrence, which is shown by high tracer uptake, and radionecrosis, shown by absent metabolic activity. 11C-Metionine uptake in malignancy is dependent on the increase in transport and metabolism of aminoacids in tumor tissue, independently of the disruption of the blood–brain barrier, thus with a potential usefulness for the evaluation of response to antiangiogenic therapies.<a class="elsevierStyleCrossRef" href="#bib0030">3</a>This case illustrates the usefulness of PET with 11C-Metionine for the detection of recurrent glioma, as well as its usefulness for the evaluation of treatment response to new second-line agents." "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-03-06" "fechaAceptado" => "2015-04-15" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: García JR, Baquero M, Bassa P, Soler M, Moragas M, Riera E. Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con 11C-metionina. Rev Esp Med Nucl Imagen Mol. 2015. http://dx.doi.org/10.1016/j.remn.2015.04.001" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 3250 "Tamanyo" => 518779 ] ] "descripcion" => array:1 [ "en" => "(A) Imaging study after Stupp treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with 11C-Methionine. MR shows a rounded lesion located at the genu of corpus callosum measuring 22×18, with adjacent bilateral frontal angiogenic edema, consistent with local recurrence. PET with 11C-Methionine shows hypermetabolic lesion (SUV target/background ratio is 5.6/1.6), thus confirming tumor recurrence. Quantification was achieved through relationship between uptake avidity of the lesion (SUV maximum) and background of gray substance of the healthy contralateral lobe (SUV mean). (B) Imaging study after Bevacizumab treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with 11C-Methionine. MR shows an increase of size at the lesion located at the genu of corpus callosum (27×24), with similar perilesional edema spread. The PET study with 11C-Methionine shows normalization of previous metabolic activity in lesion, thus confirming response to antiangiogenic treatment, and therapy was carried on with no further suspicious signs of recurrence in our patient." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:3 [ 0 => array:3 [ "identificador" => "bib0020" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemoradiotherapy in malignant glioma: standard of care and future directions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Stupp" 1 => "M.E. Hegi" 2 => "M.R. Gilbert" 3 => "A. Chakravarti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "4127" "paginaFinal" => "4136" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0025" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bevacizumab and recurrent malignant gliomas: a European perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W. Wick" 1 => "M. Weller" 2 => "M. van den Bent" 3 => "R. Stupp" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2010" "volumen" => "20" "paginaInicial" => "e188" "paginaFinal" => "e189" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0030" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuroimaging in brain tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Arbizu" 1 => "P.D. Domínguez" 2 => "R. Diez-Valle" 3 => "C. Vigil" 4 => "R. García-Eulate" 5 => "J.L. Zubieta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2010.11.001" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl" "fecha" => "2011" "volumen" => "30" "paginaInicial" => "47" "paginaFinal" => "65" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21211868" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000932/v1_201510310036/en/main.assets" "Apartado" => array:4 [ "identificador" => "7927" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Interesting images" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000003400000006/v1_201510310036/S2253808915000932/v1_201510310036/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000932?idApp=UINPBA00004N"]

ISSN: 2253-8089

The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles. The works may be submitted in Spanish or English and are subjected to a peer review process. In 2009, it became the leading Spanish journal in the field of Medical Imaging on having an Impact Factor , awarded by the Journal Citation Reports.

See more Open Access Option

Indexed in:

Science Citation Index Expander, Medline, IME, Bibliomed, EMBASE/Excerpta Medica, Healthstar, Cancerlit, Toxine, Inside Conferences, Scopus

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

1.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

1.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.208

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.273

View more metrics

Journal Information

Previous article | Next article

Lee este artículo en Español

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

Además del acceso temporal al artículo, este le será enviado por correo electrónico.

Atención al cliente

Phone

Llamadas desde España

932 415 960

Llamadas desde el extranjero

+34 932 415 960

Horario de 9 a 18h. excepto los meses de julio y agosto que será de 9 a 15h.

Publish in

Revista Española de Medicina Nuclear e Imagen Molecular

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Free access articles

Imaging of desmoplastic small round-cell tumor on

Rev Esp Med Nucl Imagen Mol. 2024;43:

Assessment of incidental cardiac uptake in bone...

Rev Esp Med Nucl Imagen Mol. 2024;43:

Diagnostic performance of a novel deep learning attenuation...

Rev Esp Med Nucl Imagen Mol. 2024;43:23-30

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter